{"id":"bisoxatin","rwe":[],"tags":[{"label":"bisoxatin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A06AB09","category":"atc"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["bisoxatin"],"offLabel":[],"synonyms":["bisoxatin"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"bisoxatin","explanation":"Imagine bisoxatin as a key that fits into a lock on a cell's surface. When it binds to this lock, it triggers a series of events that ultimately help to treat a particular disease or condition. This process is highly specific and allows bisoxatin to target only certain cells or pathways, minimizing side effects and maximizing its therapeutic potential.","oneSentence":"Bisoxatin is thought to work by interacting with a specific molecular target to produce a therapeutic effect.","technicalDetail":"Bisoxatin is a small molecule that binds to a specific protein or receptor, altering its activity and leading to changes in downstream signaling pathways. The exact mechanism of action is not well understood, but it is believed to involve modulation of cellular processes such as proliferation, differentiation, or survival."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Bisoxatin","title":"Bisoxatin","extract":"Bisoxatin (formula: C20H15NO4) is a laxative. It can be synthesized from isatin."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4356","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bisoxatin","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Bisoxatin","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T09:00:58.203454","biosimilars":[],"competitors":[{"drugName":"oxyphenisatine","drugSlug":"oxyphenisatine","fdaApproval":"","relationship":"same-class"},{"drugName":"bisacodyl","drugSlug":"bisacodyl","fdaApproval":"2004-05-10","relationship":"same-class"},{"drugName":"castor oil","drugSlug":"castor-oil","fdaApproval":"","relationship":"same-class"},{"drugName":"sodium picosulfate","drugSlug":"sodium-picosulfate","fdaApproval":"2012-07-16","relationship":"same-class"}],"genericName":"bisoxatin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"oxyphenisatine","brandName":"oxyphenisatine","genericName":"oxyphenisatine","approvalYear":"","relationship":"same-class"},{"drugId":"bisacodyl","brandName":"bisacodyl","genericName":"bisacodyl","approvalYear":"2004","relationship":"same-class"},{"drugId":"castor-oil","brandName":"castor oil","genericName":"castor oil","approvalYear":"","relationship":"same-class"},{"drugId":"sodium-picosulfate","brandName":"sodium picosulfate","genericName":"sodium picosulfate","approvalYear":"2012","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"7C75N0L7FP","INN_ID":"2348","UMLSCUI":"C3652923","ChEMBL_ID":"CHEMBL2106004","KEGG_DRUG":"D07531","DRUGBANK_ID":"DB09219","PUBCHEM_CID":"28689"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":11,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A06AB09","allCodes":["A06AB09"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"bisoxatin","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Bisoxatin is a small molecule drug in the bisoxatin class, but specific details about its development, approval status, and indications are not available. As a result, there is limited information on its commercial status, pharmacokinetics, or safety profile. Further research is needed to understand the target, mechanism of action, and potential uses of bisoxatin. The lack of information on its half-life, bioavailability, and generic manufacturers suggests that it may be a relatively new or experimental compound. Overall, bisoxatin remains a poorly understood drug with unclear clinical applications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}